Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment

Soo-Churl Cho; Bung-Nyun Kim; Tarrant Cummins; Jae-Won Kim; Mark Bellgrove

doi:10.1177/0269881111405356

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment

Soo-Churl Cho, Bung-Nyun Kim, Tarrant Cummins, Jae-Won Kim, Mark Bellgrove

Research output: Contribution to journal › Article › Research › peer-review

16 Citations (Scopus)

Abstract

The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7-1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment.

Original language	English
Pages (from-to)	380 - 389
Number of pages	10
Journal	Journal of Psychopharmacology
Volume	26
Issue number	3
DOIs	https://doi.org/10.1177/0269881111405356
Publication status	Published - 2012
Externally published	Yes

Access to Document

10.1177/0269881111405356

Cite this

@article{7423cb8d2e8143e989038596781992ac,

title = "Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment",

abstract = "The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7-1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment.",

author = "Soo-Churl Cho and Bung-Nyun Kim and Tarrant Cummins and Jae-Won Kim and Mark Bellgrove",

year = "2012",

doi = "10.1177/0269881111405356",

language = "English",

volume = "26",

pages = "380 -- 389",

journal = "Journal of Psychopharmacology",

issn = "0269-8811",

publisher = "SAGE Publications Ltd",

number = "3",

}

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. / Cho, Soo-Churl; Kim, Bung-Nyun; Cummins, Tarrant et al.
In: Journal of Psychopharmacology, Vol. 26, No. 3, 2012, p. 380 - 389.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment

AU - Cho, Soo-Churl

AU - Kim, Bung-Nyun

AU - Cummins, Tarrant

AU - Kim, Jae-Won

AU - Bellgrove, Mark

PY - 2012

Y1 - 2012

N2 - The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7-1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment.

AB - The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7-1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment.

UR - http://jop.sagepub.com/content/26/3/380.full.pdf+html

U2 - 10.1177/0269881111405356

DO - 10.1177/0269881111405356

M3 - Article

SN - 0269-8811

VL - 26

SP - 380

EP - 389

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

IS - 3

ER -

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment

Abstract

Access to Document

Other files and links

Cite this